chenodeoxycholic acid has been researched along with oxyntomodulin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burrin, DG; Holst, JJ; Jain, AK; Moore, DD; Stoll, B | 1 |
| Nakajima, A; Ogawa, Y; Okanoue, T; Sumida, Y; Yoneda, M | 1 |
1 review(s) available for chenodeoxycholic acid and oxyntomodulin
| Article | Year |
|---|---|
Current and new pharmacotherapy options for non-alcoholic steatohepatitis.
Topics: Chenodeoxycholic Acid; Clinical Trials as Topic; Fibroblast Growth Factors; Glucagon-Like Peptides; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Vitamin E | 2020 |
1 other study(ies) available for chenodeoxycholic acid and oxyntomodulin
| Article | Year |
|---|---|
Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs.
Topics: Animals; Animals, Newborn; Atrophy; Chenodeoxycholic Acid; Cholestasis; Disease Models, Animal; Fibroblast Growth Factors; Glucagon-Like Peptides; Intestinal Mucosa; Liver Diseases; Parenteral Nutrition, Total; Swine; Treatment Outcome | 2012 |